Globus Medical (GMED)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-23

$81.41-0.31%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Globus Medical’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.1%

+10% or more+5%0%−5%−10% or less

5.39 → 5.39 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	857.73M
EPS	—	1.339
Annual ending 2026-12-31
Revenue	—	3.2B
EPS	—	5
Annual ending 2027-12-31
Revenue	—	3.39B
EPS	—	5.392

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS at least $4.7 in FY26	A primary condition in Globus Medical's published investment case. The stated target is EPS >= $4.7.	Intact	EPS guidance cut below $4.5 for FY26	Diluted EPS: $1.10 per share FY2026-Q2; GAAP. Published target: EPS >= $4.7. Target period is not explicitly aligned with this observation. Source published Aug 6, 20261.1 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0118cc7f-b511-41a0-a38d-202fd9f032c8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net income growth to at least $124M in Q1 2026	Net income also grew strongly to $124M in Q1 2026.	Intact	Net income falls below $110M in any quarter	Net income: $151.569M FY2026-Q2; GAAP. Published target: Net income >= $124M in Q1 2026 and stable thereafter. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026151,569,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0118cc7f-b511-41a0-a38d-202fd9f032c8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context This priority was stated in 4 of last 4 quarters. Non-GAAP diluted EPS rose from $0.68 in 2025-Q1 to $1.34 in 2026-Q2, a near doubling. GAAP net income increased from $75.5 million to $151.6 million over the same period. Management's statements and financial results show delivering sustained earnings growth. Delivery assessment Oct 24, 2026
Operating income growth to support margin expansion	Profit margins improve, shown by operating income rising from $97M to $150M in one year.	Intact	Operating income falls below $140M in any quarter	Operating income: $182.432M FY2026-Q2; GAAP. Published target: Operating income >= $150M in Q1 2026 and sustained growth. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026182,432,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0118cc7f-b511-41a0-a38d-202fd9f032c8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to at least $3.18B in FY26	A primary condition in Globus Medical's published investment case. The stated target is >= $3.18B.	Under Pressure	Revenue falls below $3.0B in FY26	Revenue: $789.612M FY2026-Q2; GAAP. Published target: >= $3.18B. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026789,612,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0118cc7f-b511-41a0-a38d-202fd9f032c8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $598.1 million in 2025-Q1 to $789.6 million in 2026-Q2, a 32.1% increase. US Spine and International Spine segments showed strong growth in 2026-Q2. Management consistently emphasized revenue growth driven by share gains and international expansion, and the financials show delivering trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$5.39

$5.15 → $5.39 · observed estimates

FY2027 revenue$3.39B

$3.40B → $3.39B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$5.15	$3,403,956,466	8 / 10
2026-07-25	$5.15	$3,403,956,466	8 / 10
2026-07-26	$5.15	$3,405,027,890	14 / 14
2026-07-27	$5.15	$3,403,956,466	8 / 10
2026-07-28	$5.15	$3,405,027,890	14 / 14
2026-07-29	$5.14	$3,401,881,151	8 / 10
2026-07-30	$5.15	$3,405,027,890	14 / 14
2026-07-31	$5.15	$3,402,881,150	15 / 15
2026-08-01	$5.14	$3,401,881,151	9 / 11
2026-08-02	$5.15	$3,402,881,150	15 / 15
2026-08-03	$5.14	$3,401,881,151	9 / 11
2026-08-04	$5.15	$3,402,881,150	15 / 15
2026-08-05	$5.15	$3,402,881,150	15 / 15
2026-08-06	$5.15	$3,402,881,150	15 / 15
2026-08-07	$5.14	$3,401,907,818	9 / 11
2026-08-08	$5.27	$3,399,431,330	15 / 15
2026-08-09	$5.27	$3,399,431,330	15 / 15
2026-08-10	$5.27	$3,399,431,330	15 / 15
2026-08-12	$5.34	$3,391,437,160	14 / 15
2026-08-13	$5.14	$3,401,907,818	9 / 11
2026-08-14	$5.14	$3,401,907,818	9 / 11
2026-08-15	$5.14	$3,401,907,818	8 / 11
2026-08-16	$5.14	$3,401,907,818	8 / 11
2026-08-17	$5.14	$3,401,907,818	8 / 11
2026-08-18	$5.14	$3,401,907,818	8 / 11
2026-08-19	$5.14	$3,401,907,818	8 / 11
2026-08-20	$5.35	$3,391,419,845	8 / 11
2026-08-21	$5.35	$3,391,419,845	8 / 11
2026-08-22	$5.35	$3,391,417,098	8 / 11
2026-08-23	$5.35	$3,391,417,098	8 / 11
2026-08-24	$5.35	$3,391,417,098	8 / 11
2026-08-25	$5.35	$3,391,646,631	8 / 11
2026-08-26	$5.35	$3,391,646,631	8 / 11
2026-08-27	$5.35	$3,391,646,631	8 / 11
2026-08-28	$5.35	$3,391,646,631	8 / 11
2026-08-29	$5.38	$3,392,633,298	8 / 11
2026-08-30	$5.38	$3,392,633,298	8 / 11
2026-08-31	$5.38	$3,392,633,298	8 / 11
2026-09-01	$5.38	$3,392,633,298	8 / 11
2026-09-02	$5.38	$3,392,633,298	8 / 11
2026-09-03	$5.38	$3,392,633,298	8 / 11
2026-09-04	$5.38	$3,392,633,298	8 / 11
2026-09-05	$5.38	$3,392,633,298	8 / 11
2026-09-06	$5.38	$3,392,633,298	8 / 11
2026-09-07	$5.38	$3,392,633,298	8 / 11
2026-09-08	$5.38	$3,392,633,298	8 / 11
2026-09-09	$5.38	$3,392,633,298	8 / 11
2026-09-10	$5.39	$3,392,633,298	8 / 11
2026-09-11	$5.39	$3,392,633,298	8 / 11
2026-09-12	$5.39	$3,392,633,298	8 / 11
2026-09-13	$5.39	$3,392,633,298	8 / 11
2026-09-14	$5.39	$3,392,633,298	8 / 11
2026-09-15	$5.39	$3,392,633,298	8 / 11
2026-09-16	$5.39	$3,392,633,298	8 / 11
2026-09-17	$5.39	$3,392,633,298	8 / 11
2026-09-18	$5.39	$3,392,633,298	8 / 11
2026-09-19	$5.39	$3,392,633,298	8 / 11
2026-09-20	$5.39	$3,392,636,031	8 / 11
2026-09-21	$5.39	$3,392,636,031	8 / 11
2026-09-22	$5.39	$3,392,636,031	8 / 11
2026-09-23	$5.39	$3,392,636,031	8 / 11
2026-09-24	$5.39	$3,392,636,031	8 / 11
2026-09-25	$5.39	$3,392,636,031	8 / 11
2026-09-26	$5.40	$3,392,636,031	8 / 11
2026-09-27	$5.40	$3,392,636,031	8 / 11
2026-09-28	$5.40	$3,392,636,031	8 / 11
2026-09-29	$5.40	$3,392,636,031	8 / 11
2026-09-30	$5.40	$3,392,636,031	8 / 11
2026-10-01	$5.40	$3,392,636,031	8 / 11
2026-10-02	$5.40	$3,392,636,031	8 / 11
2026-10-03	$5.40	$3,392,636,031	8 / 11
2026-10-04	$5.40	$3,392,636,031	8 / 11
2026-10-05	$5.40	$3,392,636,031	8 / 11
2026-10-06	$5.40	$3,392,636,031	8 / 11
2026-10-07	$5.40	$3,392,636,031	8 / 11
2026-10-08	$5.40	$3,392,636,031	8 / 11
2026-10-09	$5.40	$3,392,636,031	8 / 11
2026-10-10	$5.40	$3,392,636,031	8 / 11
2026-10-11	$5.40	$3,392,636,031	8 / 11
2026-10-12	$5.40	$3,392,636,031	8 / 11
2026-10-13	$5.40	$3,392,636,031	8 / 11
2026-10-14	$5.40	$3,392,636,031	8 / 11
2026-10-15	$5.40	$3,392,636,031	8 / 11
2026-10-16	$5.40	$3,392,636,031	8 / 11
2026-10-17	$5.40	$3,392,636,031	8 / 11
2026-10-18	$5.39	$3,392,824,319	8 / 11
2026-10-19	$5.39	$3,392,824,319	8 / 10
2026-10-20	$5.39	$3,392,824,319	8 / 10
2026-10-21	$5.39	$3,392,824,319	8 / 10
2026-10-22	$5.39	$3,392,824,319	8 / 10
2026-10-23	$5.39	$3,392,824,319	8 / 10
2026-10-24	$5.39	$3,392,824,319	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	4
2026-06-01	9	4
2026-07-01	10	5
2026-08-01	10	5
2026-09-01	10	5
2026-10-01	10	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 1 · prior Jul 13

$115.00 → $85.00-26.1%

$0$63.25$126.50

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS at least $4.7 in FY26Diluted EPS: $1.10 per share
Net income growth to at least $124M in Q1 2026Net income: $151.569M
Operating income growth to support margin expansionOperating income: $182.432M
Revenue growth to at least $3.18B in FY26Published status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-24.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Globus Medical outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

GMED is a growth-oriented medical-device business with recent strength in revenue, earnings, and margins. Its long-term thesis is intact, with management priorities on track and recent results in the top half of its industry.

What's priced into Globus Medical

The evidence describes GMED as cheap versus peers, with no signs that the valuation is especially fragile. The expectations gap is negative, which suggests market expectations may be below the company’s current fundamental picture, though confidence in this reading is medium.

What the fundamentals likely do

Near term, continued execution is supported by two recent earnings beats and rising revenue, operating income, margins, and earnings per share. The main risk is a guidance cut after the recent raise, which could weaken confidence; the snapshot also notes that peers have missed recently and GMED has had a deep miss in its past.

What Globus Medical hinges on

Over the next 1 to 3 years, the thesis hinges on continued share gains and international expansion, alongside further operating margin growth. Near-term evidence could strengthen if healthcare bellwethers keep reporting well, while weakening employment data could increase recession concerns for cyclical businesses.